Cargando…

Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men

Aim: The aim of the study was to investigate pharmacokinetics of terbutaline after oral and inhaled administration in healthy trained male subjects in relation to doping control. Methods: Twelve healthy well-trained young men (27 ±2 years; mean ± SE) underwent two pharmacokinetic trials that compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyreborg, Anders, Krogh, Nanna, Backer, Vibeke, Rzeppa, Sebastian, Hemmersbach, Peter, Hostrup, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901060/
https://www.ncbi.nlm.nih.gov/pubmed/27375484
http://dx.doi.org/10.3389/fphar.2016.00150
_version_ 1782436735296208896
author Dyreborg, Anders
Krogh, Nanna
Backer, Vibeke
Rzeppa, Sebastian
Hemmersbach, Peter
Hostrup, Morten
author_facet Dyreborg, Anders
Krogh, Nanna
Backer, Vibeke
Rzeppa, Sebastian
Hemmersbach, Peter
Hostrup, Morten
author_sort Dyreborg, Anders
collection PubMed
description Aim: The aim of the study was to investigate pharmacokinetics of terbutaline after oral and inhaled administration in healthy trained male subjects in relation to doping control. Methods: Twelve healthy well-trained young men (27 ±2 years; mean ± SE) underwent two pharmacokinetic trials that compared 10 mg oral terbutaline with 4 mg inhaled dry powder terbutaline. During each trial, subjects performed 90 min of bike ergometer exercise at 65% of maximal oxygen consumption. Blood (0–4 h) and urine (0–24 h) samples were collected before and after administration of terbutaline. Samples were analyzed for concentrations of terbutaline by high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). Results: Pharmacokinetics differed between the two routes of administration. Serum C(max) and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (C(max): 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min). Urine concentrations (sum of the free drug and the glucuronide) were lower after oral administration compared to inhalation 2 h (1100 ± 204 vs. 61 ± 10 ng/ml, P ≤ 0.05) and 4 h (734 ± 110 vs. 340 ± 48 ng/ml, P ≤ 0.001) following administration, whereas concentrations were higher for oral administration than inhalation 12 h following administration (190 ± 41 vs. 399 ± 108 ng/ml, P ≤ 0.05). Urine excretion rate was lower after oral administration than inhalation the first 2 h following administration (P ≤ 0.001). Systemic bioavailability ratio between the two routes of administration was 3.8:1 (inhaled: oral; P ≤ 0.001). Conclusion: Given the higher systemic bioavailability of inhaled terbutaline compared to oral, our results indicate that it is difficult to differentiate allowed inhaled use of terbutaline from prohibited oral ingestion based on urine concentrations in doping control analysis. However given the potential performance enhancing effect of high dose terbutaline, it is essential to establish a limit on the WADA doping list.
format Online
Article
Text
id pubmed-4901060
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49010602016-07-01 Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men Dyreborg, Anders Krogh, Nanna Backer, Vibeke Rzeppa, Sebastian Hemmersbach, Peter Hostrup, Morten Front Pharmacol Pharmacology Aim: The aim of the study was to investigate pharmacokinetics of terbutaline after oral and inhaled administration in healthy trained male subjects in relation to doping control. Methods: Twelve healthy well-trained young men (27 ±2 years; mean ± SE) underwent two pharmacokinetic trials that compared 10 mg oral terbutaline with 4 mg inhaled dry powder terbutaline. During each trial, subjects performed 90 min of bike ergometer exercise at 65% of maximal oxygen consumption. Blood (0–4 h) and urine (0–24 h) samples were collected before and after administration of terbutaline. Samples were analyzed for concentrations of terbutaline by high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). Results: Pharmacokinetics differed between the two routes of administration. Serum C(max) and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (C(max): 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min). Urine concentrations (sum of the free drug and the glucuronide) were lower after oral administration compared to inhalation 2 h (1100 ± 204 vs. 61 ± 10 ng/ml, P ≤ 0.05) and 4 h (734 ± 110 vs. 340 ± 48 ng/ml, P ≤ 0.001) following administration, whereas concentrations were higher for oral administration than inhalation 12 h following administration (190 ± 41 vs. 399 ± 108 ng/ml, P ≤ 0.05). Urine excretion rate was lower after oral administration than inhalation the first 2 h following administration (P ≤ 0.001). Systemic bioavailability ratio between the two routes of administration was 3.8:1 (inhaled: oral; P ≤ 0.001). Conclusion: Given the higher systemic bioavailability of inhaled terbutaline compared to oral, our results indicate that it is difficult to differentiate allowed inhaled use of terbutaline from prohibited oral ingestion based on urine concentrations in doping control analysis. However given the potential performance enhancing effect of high dose terbutaline, it is essential to establish a limit on the WADA doping list. Frontiers Media S.A. 2016-06-10 /pmc/articles/PMC4901060/ /pubmed/27375484 http://dx.doi.org/10.3389/fphar.2016.00150 Text en Copyright © 2016 Dyreborg, Krogh, Backer, Rzeppa, Hemmersbach and Hostrup. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dyreborg, Anders
Krogh, Nanna
Backer, Vibeke
Rzeppa, Sebastian
Hemmersbach, Peter
Hostrup, Morten
Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men
title Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men
title_full Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men
title_fullStr Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men
title_full_unstemmed Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men
title_short Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men
title_sort pharmacokinetics of oral and inhaled terbutaline after exercise in trained men
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901060/
https://www.ncbi.nlm.nih.gov/pubmed/27375484
http://dx.doi.org/10.3389/fphar.2016.00150
work_keys_str_mv AT dyreborganders pharmacokineticsoforalandinhaledterbutalineafterexerciseintrainedmen
AT kroghnanna pharmacokineticsoforalandinhaledterbutalineafterexerciseintrainedmen
AT backervibeke pharmacokineticsoforalandinhaledterbutalineafterexerciseintrainedmen
AT rzeppasebastian pharmacokineticsoforalandinhaledterbutalineafterexerciseintrainedmen
AT hemmersbachpeter pharmacokineticsoforalandinhaledterbutalineafterexerciseintrainedmen
AT hostrupmorten pharmacokineticsoforalandinhaledterbutalineafterexerciseintrainedmen